Navigation Links
Patients are living longer with ICDs, but pacing impacts survival rates
Date:8/27/2011

The adverse effect of right ventricular pacing on implantable cardioverter-defibrillator (ICD) patient survival is sustained long-term; however, the impact appears to be mitigated by cardiac resynchronization therapy (CRT), based on a scientific poster being presented at the European society of Cardiology (ESC) Congress Aug 28 in Paris.

"We were pleased to discover that the average patient, despite having severe left ventricular dysfunction, lived nine years after ICD implantation, which are the best results that we are aware of," according to lead author Robert G. Hauser, MD, cardiac electrophysiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis.

The researchers followed all 1,395 ICD patients at Minneapolis Heart Institute who were 18 years or older with ejection fraction 35 percent or greater between 2000 and 2009. Of these patients, 673 had ICD-CRT and were paced in both lower chambers of the heart; 468 patients had single or dual chamber ICDs and most were paced in the right ventricle less than 10 percent of the time; and 59 had single or dual chamber ICDs and were paced in the right ventricle continuously.

The study had two objectives: the predictors of survival in this population and the effect of right ventricular pacing on survival.

Importantly, the researchers found that survival of CRT patients was similar to single and dual chamber ICD patients paced less than 10 percent of the time. Patients who were paced continuously in the right ventricle did not live as long as either the CRT patients or the patients who were infrequently paced in the right ventricle. "Thus, pacing had an adverse effect on survival," Hauser said. "We also found that if the right and the left side of the heart were paced in synchrony, the patients fared better."

Other factors associated with improved survival were treatment with an ACE inhibitor or an ARB; the age of the patient, meaning those
'/>"/>

Contact: Kristin Wincek
kwincek@mhif.org
612-863-0249
Minneapolis Heart Institute Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. ICU Patients at Risk for Rare Heart Rhythm Problem
2. Young patients with chronic illnesses find relief in acupuncture
3. For Some Breast Cancer Patients, Shorter Radiation Works Well
4. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
5. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
6. Behavioral therapy improves sleep and lives of patients with pain
7. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
8. MSU researcher linking breast cancer patients with alternative therapies
9. New American Heart Association Survey Finds Heart Disease and Stroke Patients Face Significant Barriers in Obtaining Quality, Affordable Care
10. Fishy Smell May Keep Patients From Diabetes Drug
11. AGA offers new recommendations for CRC surveillance for certain patients with IBD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have ... Miller Place, N.Y. "I specialize in manual therapy, and my invention will provide ... be used for additional muscle dysfunction throughout the body." , They developed THE ...
(Date:8/29/2015)... ... 2015 , ... Next weekend is Labor Day weekend, the last bash of ... 22nd this year). For IT security personnel, it should also mark the perfect time ... more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... ... 29, 2015 , ... Vascular Health Sciences announced today that ... Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. , ... in the United States District Court for the Southern District of Texas for ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... ,Genzyme Corporation (Nasdaq: GENZ ) and Bioenvision, ... Bioenvision stockholders have voted to,approve the acquisition of ... meeting in New York. The transaction will be ... the company will,be delisted from Nasdaq. Fifty-six ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced today ... of iloperidone at the 57th American Society of ... San Diego, CA, from October 23,through October 27, ... filing for iloperidone on September 27, 2007. Iloperidone ...
... evacuees to register on Safe and Well Website, ... California, forcing thousands to evacuate the area. During this,ongoing ... may feel confused,and anxious about the safety of their ... all those who have evacuated or who expect to,evacuate ...
... A team of Johns Hopkins scientists reports in this weeks ... that humans can be protected against the damaging effects of ... our environment by topical application of an extract of ... by parallel evidence obtained in mice, show that the degree ...
... 22 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: ... (ADHD), announced today that it will present key,scientific ... scientific and,educational meeting of child and adolescent psychiatrists ... Shire studies to be presented are indicative of ...
... 22 HealthShares(TM) Inc., an investment,company with a series ... informed by Standard & Poor,s, the calculating agent for ... on,Thursday October 25, 2007, Amag Pharmaceuticals (Nasdaq: AMAG ... the HealthShares(TM) Diagnostics Index, and,Hologic Inc. (Nasdaq: HOLX ...
Cached Medicine News:Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 2Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 3Health News:Southern California Wildfires Continue to Threaten Residential Areas 2Health News:Southern California Wildfires Continue to Threaten Residential Areas 3Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 3Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 4Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 5Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 2Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 3
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... ADDISON, Texas and SALT LAKE CITY, Feb. 28, 2011 ... HUM ), is transforming the future of occupational ... improvements, creating exceptional and engaging experiences for clients and ... Concentra has joined the ranks of top U.S. consumer ...
... 28, 2011 ViroPharma Incorporated (Nasdaq: VPHM ) ... of ViroPharma, will present at the Citi 2011 Global Healthcare ...  The conference is being held at the Hilton New York ... president and chief financial officer, of ViroPharma, will present at ...
Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5ViroPharma to Participate in Two March Healthcare Conferences 2
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: